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Single nucleotide polymorphisms (SNPs), R990G and A986S of the calcium sensing receptor (CaSR) gene, are shown to influence
response of parathyroid hormone (PTH) in subjects with optimal vitamin D levels. This cross-sectional study was conducted in
subjects with vitaminDdeficiency (VDD) to observe associations betweenCaSR polymorphisms, plasma iPTH, and serum calcium
levels. Adult females (𝑛 = 140) with known VDD, intact parathyroid hormone (iPTH), and calcium levels were recruited for
genotype analysis.The frequencies of the 986 alleles GG, GT, and TT were 68%, 25%, and 7%, respectively, whereas the frequencies
of the 990 alleles AA, AG, andGGwere 80%, 8.9%, and 11.1%, respectively.The subjects with GG genotype of R990G polymorphism
had higher iPTH levels (148.65 versus 91.47 and 86.1 pg/mL for GG versus AA, AG, resp., 𝑃 = 0.008) and lower calcium levels (8.4
versus 9.04 and 9.07mg/dL for GG versus AA, AG, resp., 𝑃 = 0.002). No such association of A986S polymorphism with plasma
iPTH or serum calcium levels was observed in the present study. Patients with VDD bearing the GG genotype of R990G SNPs are
prone to have higher iPTH levels and lower calcium.
1. Introduction
Vitamin D deficiency has been reported from Pakistan in
healthy volunteers, patients, and community females [1–
3]. In those studies, a variable proportion (25.9%–31%) of
the subjects demonstrated secondary hyperparathyroidism
(SHPT), as a compensatory response to VDD. On the
contrary, a significant number of subjects with VDD did
not show SHPT (blunted PTH response), a phenomenon
described in literature as functional hypoparathyroidism [4].
Several reasons have been reported for the inconsistent PTH
response to VDD. Factors causing functional hypoparathy-
roidism include abnormalities of the CaSR or vitamin D
receptor, magnesium deficiency, and renal dysfunction [4, 5].
The focus of our study is the CaSR.
The main physiological function of parathyroid gland
is maintaining blood calcium levels within a narrow range,
by modulating minute-to-minute release of PTH into the
circulation.
The CaSR has been shown to play a key role in calcium
homeostasis by regulating PTH secretion. It is a G-protein
coupled receptor, which is expressed in many cell types
associated with maintaining calcium homeostasis, including
parathyroid cells, kidney, and osteoblasts [6]. Patients with
functional hypoparathyroidism show a minimum secretion
rate of PTH in the presence of low or low normal calcium
as compared to subjects with SHPT. This indicates abnormal
calcium sensing which can occur due to changes in genetic
makeup of CaSR. Recent studies have shown association of
SNPs in CaSR gene with serum levels of PTH and calcium
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[7–9]; small increments in extracellular calcium above nor-
mal would lead to activation of CaSR which prevents imme-
diate secretion of PTH, gene transcription, and proliferation
of parathyroid cells [10, 11].
Several SNPs regulating CaSR gene are reported in the
Caucasians; of those A986S and R990G are most frequently
studied. These variant alleles have been studied in different
groups including normal individuals, subjects with primary
hyperparathyroidism, and kidney stone formers [12, 13]. To
the best of our knowledge, there is no published report
exploring the association of CaSR linked SNPs with SHPT in
subjects with VDD.
We hypothesized that variable PTH secretion in VDD
subjects is influenced by the SNPs located in the CaSR gene.
Therefore, this study was conducted to explore an association
between SNPs A986S and R990G with PTH and calcium
levels in Pakistani females confirmed with VDD.
2. Materials and Methods
2.1. Study Design and Population. A cross-sectional study
was conducted between January 2012 and September 2012 in
the Sections of Chemical and Molecular Pathology, Depart-
ment of Pathology and Microbiology, Aga Khan University,
Karachi, Pakistan. A total of 140 premenopausal female
subjects, ≥18 years of age (age range 18–48 years) with
VDD (25 OHD level < 20 ng/mL), were analyzed for SNPs
in the CaSR gene. Subjects with any medical disorder of
bone minerals, such as primary hyperparathyroidism or
hypoparathyroidism, were excluded from the study. Females
taking any medications known to affect calciummetabolism,
such as calcium tablets or bisphosphonate, and vitamin D
supplements, individuals on hormonal therapy, and pregnant
femaleswere also excluded.The studywas approved by ethical
review committee of the Aga Khan University Hospital (ERC
approval number: 2155-Path-ERC-12).
2.2. DNA Extraction and Genotyping Procedure. Genomic
DNA was extracted from WBC obtained from blood speci-
mens of the participants using a DNA isolation kit, according
to the manufacturer’s instructions (Promega, Madison, WI,
USA). Purified DNAwas stored at −20∘C for further process-
ing.
The SNPs A986S and R990G located in the exon 7 of
CaSR gene were analyzed by RFLP-PCR using published
protocols [14]. A986S polymorphism represents substitution
of alanine with serine (replacement of nucleotide G with
T) at position 986, whereas R990G polymorphism is sub-
stitution of arginine with glycine (replacement of nucleotide
A with G) at position 990. Restriction enzymes Hsp-921
(Promega, Madison, WI, USA) and Btg-I (New England
Biolabs, Hitchin, UK) were used for the analysis of A986S
and R990G polymorphisms, respectively. Restriction assay
was performed in a total volume of 25𝜇L containing 15 𝜇L
PCR product, 3 𝜇L buffer, 0.2 𝜇L BSA, 11.3 𝜇L nuclease free
water, and 5 units of the specific enzyme. Reaction mix was
incubated overnight in water bath at 37∘C. Restriction prod-
ucts were then analyzed by 3% agarose gel electrophoresis.
A986S genotypes included GG, GT, and TT, whereas R990G
genotypes were AA, AG, or GG. All assays were examined
with appropriate controls.
2.3. Biochemical Analysis. Serum 25-OHD levels were mea-
sured by electrochemiluminescence immunoassay on Elecsys
auto analyzer (Roche Diagnostics, Basel, Switzerland). For
quality assessment, low,medium, andhighElecsys Preci Con-
trols were used. The within-run CVs were 5.7%, 5.7%, and
5.4% at concentrations of 25.2, 39.9, and 65.6 ng/mL. A cutoff
of <20 ng/mL for 25OHD was considered to be deficient.
Plasma intact parathyroid hormone (iPTH) levels were mea-
sured by Immulite 2000 (Siemens Healthcare Diagnostics
Inc., NY, USA). Two levels manufacturer provided controls
were run for quality assessments. The intra-assay precision
was 5.5%; an interassay precision was 7.9%. The reference
range of iPTH assay was 16–87 pg/mL. Plasma iPTH levels
above 87 pg/mL were considered as hyperparathyroidism,
while SHPT was defined as subjects with low or normal
calcium and deficient 25OHD levels and PTH >87 pg/mL.
Serum calcium levels were measured on Advia 1800
Chemistry Analyzer (Siemens Healthcare Diagnostics Inc.,
NY, USA). Two levels manufacturer provided controls were
run for quality assessments. For the period of study, external
quality was assured by simultaneously analyzing samples
for 25OHD, iPTH, and calcium from College of American
Pathologist (CAP, USA) three times a year.
2.4. Data Analysis. Data was analyzed by statistical package
for social sciences (SPSS) version 19 for Windows (IMB,
Chicago, IL, USA). For quantitative variables (age, BMI,
creatinine, calcium, iPTH, and vitamin D levels), mean and
standard deviation were calculated. Distribution of SNPs
was compared with iPTH, calcium, and 25OHD levels using
one way analysis of variance, taking R990G and A986S as
dichotomizing factors and iPTH, calcium, and 25OHD as
dependent variables. Online software SNPstats [15] was used
to perform Fisher’s exact test for computing Hardy-Weinberg
equilibrium and association analyses for iPTH, calcium, and
25OHD levels with the different haplotypes.
3. Results
The baseline biochemical data of the 140 women enrolled
in the study is shown in Table 1. All the participants were
vitamin D deficient. The mean creatinine and calcium levels
were within normal limits. According to South Asian Clas-
sification, most of the women were overweight. The mean
iPTH level of the participants was slightly higher compared
to the upper limit of the reference range used; of them 45% of
the women had raised iPTH (mean iPTH 145.3 ± 9.5 pg/mL)
and 55% had iPTH levels within reference range (mean iPTH
59.9 ± 17.2 pg/mL).
3.1. Frequency of A986S and R990G Genotypes. The allelic
frequency of A986S SNPs for nucleotides G and T was 76%
and 24%, respectively. Genotype GG of SNP A986S was most
frequent (68%) in the study group, followed by GT (25%) and
TT (7%). The A986S genotype incidence was in accordance
with the Hardy-Weinberg equilibrium (Fisher’s exact test,
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Table 1: Anthropometric and biochemical data of study subjects.
Variable (reference range) Mean ± SD
𝑛 = 140
Age (years) 31 ± 8.2
BMI (kg/m2) 24.2 ± 5.4
Serum 25OHD 8.4 ± 7.7
(Vitamin D deficiency <20 ng/mL)
Plasma PTH 96.2 ± 66
(normal values 16–87 pg/mL)
Serum calcium 9 ± 0.6
(normal values 8.6–10.2mg/dL)
Serum creatinine 0.8 ± 0.2
(normal values 0.6–1.2mg/dL)
∗South Asian classification of BMI.
𝑃 = 0.46). Allelic frequency for R990G SNPs for nucleotides
A and G was 72% and 28%, respectively. The frequency of
genotype AA of R990G was observed in 80% participants,
whereas the genotypes AG andGGwere found in 9% and 11%
of women, respectively. However, these genotypes were not in
Hardy-Weinberg equilibrium (𝑃 value < 0.0001).
3.2. Effects of SNPs on iPTH and Calcium Levels. Tables 2 and
3 show analysis of calcium, iPTH, and 25OHD levels grouped
according to A986S and R990G genotypes, respectively.
Comparison of A986S genotypes showed no statistically
significant difference in three genotypes for iPTH, calcium,
and vitamin D.
Comparison of participants among the three genotypes of
R990G SNP revealed that serum iPTH levels are significantly
higher in GG compared to AG and AA genotypes (148.65
versus 90.39 and 86.1 pg/mL, 𝑃 = 0.008). In addition,
decreased calcium levels (8.47 versus 9.07mg/dL, 𝑃 = 0.002)
were seen in subjects with GG genotype, while statistically
nonsignificant difference in 25OHD levels within the three
genotypes was noted.
The commonest R990G:A986S haplotype found in our
population was A:G. The quantitative variables were com-
pared in individuals with different haplotypes, taking A:G
as the reference group (Table 4). Intact PTH levels were
significantly higher in individuals carrying G:G haplotypes
when compared with A:G haplotype subjects (mean PTH
132.34 ± 118.5 pg/mL versus 86 ± 47.5 pg/mL, 𝑃 = 0.0048).
Serum calcium concentration was significantly lower in
individuals carrying haplotype G:T (mean calcium 9.05 ±
0.48 versus 8.27 ± 1.96mg/dL, 𝑃 = 0.0079) compared to
participants with haplotype A:G.
Decreasing levels of calcium were found in haplotypes
observed in the following order: A:T > A:G > G:G > G:T,
while gradual iPTH increase was seen in the following
haplotypes: G:T > G:G > A:T > A:G.
4. Discussion
Analysis of genetic polymorphisms associations and disease
states or alterations in physiological and other variables
can provide clues into disease pathogenesis, which can be
explored further by experimental approaches. There have
been a number of studies examining associations of CaSR
polymorphisms with variables such as serum calcium con-
centrations, PTH levels, severity of primary hyperparathy-
roidism, calcium excretion, renal stones, fractures, bone
mineral density, and risk of colon cancer [8, 12, 13, 16]. All
of these are conducted in vitamin D sufficient individuals; so
far there is no study reported in literature that has reported
association of CaSR polymorphisms with PTH and calcium
levels in subjects with VDD.
In parathyroid tissue, vitamin D and calcium have been
recognized as key modifiers of PTH gene transcription,
hormone synthesis, and parathyroid cell proliferation. Recent
literature shows that all the effects of extra cellular cal-
cium are mediated through CaSR [6]. The role of CaSR in
parathyroid tissue extends beyond its traditional role as a
modifier of calcium regulated PTH secretion and involves
other components of parathyroid gland function which are
frequently abnormal in clinical disorders characterized by
excess parathyroid gland activity such as hyperparathy-
roidism. The SHPT is a normal compensatory response in
VDD, which maintains serum calcium levels but at the
expense of decreasing mineral content of bone, causing
bone thinning and early osteoporosis especially in females
[1, 17, 18]. On the other hand, subjects with functional
hypoparathyroidism are shown to have higher bone mineral
density compared with those having SHPT [4, 19].
The frequencies of A986S and R990G SNPs in our
population were close to their distribution in Caucasians and
Asian population (16.5% and 4.5% versus 7% for A986S and
8.4% and 42.9% versus 11.1% for R990G SNP, resp.) [20].
Major aim of the present study was to investigate whether a
given genotype has a role in determining the interrelationship
between levels of iPTH, calcium, and vitamin D. The GG
genotype of R990G SNP was found to be associated with
higher mean iPTH levels. Only 16 subjects were identified
with GG genotype of R990G polymorphism and 12 out
of 16 subjects had higher than normal mean iPTH levels.
Since the degree of the disequilibrium was small, therefore,
the small number of homozygotes could have confounded
interpretation of the genotype-analyte association. Subjects
with GG genotype of R990G polymorphisms had lower
mean calcium levels despite SHPT. This finding could have
been due to the increased excretion of calcium in subjects
with R990G polymorphism, as reported in multiple studies.
Subjects with vitaminD deficiency carrying the GG genotype
may develop lower calcium serum levels than patients with
other genotypes because patients have two hypocalcemic
stimuli, the low vitamin D level and the 990G allele. PTH
secretion could be secondarily stimulated in these patients.
The SHPT due to VDD is treated with calcium and
vitamin D supplements. However, recently in patients on
hemodialysis due to CKD [21], CaSR based therapeutics (cal-
cimimetics) provides better therapy options by modulating
PTH secretion rather than just supportive treatment [22, 23].
Calcimimetics are orally active agonists of the CaSR, used for
treating PTH hypersecretion in end stage kidney disease and
parathyroid carcinoma by enhancing receptor sensitivity to
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Table 2: Frequency and distribution of plasma iPTH, serum calcium, and serum 25OHD levels in CaSR SNP, A986S genotypes.
Analytes A986S polymorphism 𝑃 value
GG (𝑛 = 95) GT (𝑛 = 35) TT (𝑛 = 10)
Plasma iPTH (pg/mL) 92.4 ± 63.2 100.7 ± 79.1 116 ± 66.4 0.53
Serum calcium (mg/dL) 8.99 ± 0.4 9.0 ± 1 9.1 ± 0.3 0.85
Serum 25OHD (ng/mL) 5.6 ± 8.1 8.4 ± 7.5 8.7 ± 6 0.49
One way analysis of variance was performed with post hoc analysis by Tukey’s test.
𝑃 value < 0.05 was considered statistically significant.
Table 3: Frequency and distribution of plasma iPTH, serum calcium, and serum 25OHD levels in CaSR SNP, R990G genotypes.
Analytes R990G polymorphism 𝑃 value
AA (𝑛 = 112) AG (𝑛 = 12) GG (𝑛 = 16)
Plasma iPTH (pg/mL) 90.4 ± 58.5 86.1 ± 58 148.7 ± 66.4 0.008
Serum calcium (mg/dL) 9.1 ± 0.3 9.1 ± 0.3 8.5 ± 0.4 0.002
Serum 25OHD (ng/mL) 8.3 ± 12.1 6.7 ± 7.1 11 ± 8.2 0.37
One way analysis of variance was performed with post hoc analysis by Tukey’s test.
Tukey’s test showed mean difference of iPTH and calcium levels were significantly different in GG genotype.
𝑃 value < 0.05 was considered statistically significant.
Table 4: Association of R990G:A986S haplotype with plasma iPTH, serum calcium, and serum 25OHD levels.
R990G:A986S Frequency
Mean plasma
iPTH difference
pg/mL (95% CI)
𝑃 value
Mean serum
calcium difference
mg/dL (95% CI)
𝑃 value
Mean serum
25OHD difference
(95% CI)
𝑃 value
A:G 0.68 0.00 — 0.00 — 0.00 —
A:T 0.17 15.3(−7.06–37.64) 0.18
0.1
(−0.07–0.26) 0.25
−1.5
(−3.8–0.77) 0.2
G:G 0.12 49.4(11.57–61.83) 0.0049
−0.11
(−0.29–0.08) 0.26
−0.9
(−3.63–1.69) 0.48
G:T 0.03 36.7(0.48–98.4) 0.05
−0.51
(−0.88–−0.14) 0.0079
−1.6
(−7.24–3.96) 0.57
Haplotype association with quantitative variables was computed using online SNPstats software taking A:G haplotype as a reference.
𝑃 value < 0.05 was considered statistically significant.
extracellular calcium and inhibiting PTH secretion. Several
studies have shown that polymorphisms in carboxyl end
terminal of CaSR gene can lead to increased sensitivity of
those individuals to calcimimetics [24, 25].
In the present study, we found that the G:G haplotype
is significantly associated with high iPTH levels, suggesting
that it is a susceptibility marker for the development of
SHPT. While the G:T haplotype was associated with lower
calcium levels, whether it is exclusively mediated by a
decreased inhibitory effect of the G:T haplotype of CASR
on suppression of PTH secretion with subsequent decreased
mobilization of calcium cannot be assessed from our data,
especially given the bias due to inclusion of subjects with
VDD only.
Strengths of this study are that only subjects with VDD
(which is very common in Pakistan) were included and
association of these polymorphisms with SHPT was deter-
mined. Accuracy of reaction was validated by using controls.
To identify controls, 10 samples after similar PCR reaction
and digestion controls as samples of study subject were
analysed by agarose gel electrophoresis and for confirmation
were rerun on 1.5% Precast Polyacrylamide Gel (Bio-Rad
Laboratories Inc., USA). The samples identified as having
A986S (genotype GT or TT) and R990G polymorphisms
(genotype AG or GG) were then stored and run as controls
with each batch of PCR reaction and electrophoresis.
Genetic and environmental covariates in specific popu-
lations can affect associational observations. The clinical sig-
nificance of these polymorphisms in prediction of disorders
affecting bone and mineral metabolism and homoeostasis of
bone minerals needs to be explored.
In conclusion, patients with VDD bearing the GG geno-
type of R990GSNPhave higher plasma iPTH levels and lower
serum calcium in comparison with the AG and AA genotype
subjects. Secondly, the presence of SHPT in our population is
found to be associated with CaSR gene polymorphism.
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